Terms: = Bone cancer AND EML4, ENSG00000143924, 27436 AND Treatment
12 results:
1. Transformation of NSCLC to SCLC harboring eml4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
[TBL] [Abstract] [Full Text] [Related]
2. A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease.
Sun W; Zheng J; Zhou J; Zhou J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 52(5):583-587. PubMed ID: 37899398
[TBL] [Abstract] [Full Text] [Related]
3. Response to treatment with an ALK-TKI in a patient with advanced lung adenocarcinoma with concurrent ALK fusion and high PD-L1 expression: A case report.
Zhang Y; Fang H; Hong J; Wang X; Wang H; Pan G
Medicine (Baltimore); 2022 Aug; 101(33):e30094. PubMed ID: 35984185
[TBL] [Abstract] [Full Text] [Related]
4. BRAF V600E mutation as a novel mechanism of acquired resistance to ALK inhibition in ALK-rearranged lung adenocarcinoma: A case report.
Sui A; Song H; Li Y; Guo L; Wang K; Yuan M; Chen R
Medicine (Baltimore); 2021 Feb; 100(8):e24917. PubMed ID: 33663128
[TBL] [Abstract] [Full Text] [Related]
5. Minimal Residual Disease Monitoring Using a 3'ALK Universal Probe Assay in ALK-Positive Anaplastic Large-Cell Lymphoma: ddPCR, an Attractive Alternative Method to Real-Time Quantitative PCR.
Quelen C; Grand D; Sarot E; Brugières L; Sibon D; Pradines A; Laurent C; Brousset P; Lamant L
J Mol Diagn; 2021 Feb; 23(2):131-139. PubMed ID: 33246076
[TBL] [Abstract] [Full Text] [Related]
6. Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and eml4-ALK rearrangement.
Bronte G; Delmonte A; Burgio MA; Verlicchi A; Puccetti M; Bravaccini S; Cravero P; Tumedei MM; Diano D; Rossi G; Ulivi P; Martinelli G; Crinò L
Lung Cancer; 2020 Apr; 142():47-50. PubMed ID: 32088605
[TBL] [Abstract] [Full Text] [Related]
7. ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: A case report.
Qiu Y; Li B; Zhang Y; Guo X; Xiang C; Wang C; Lu Y; Ren S; Zhao J
Medicine (Baltimore); 2019 Mar; 98(11):e14826. PubMed ID: 30882666
[TBL] [Abstract] [Full Text] [Related]
8. A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature review.
Xu CW; Cai XY; Shao Y; Li Y; Shi MW; Zhang LY; Wang L; Zhang YP; Wang LP; Tian YW
Mol Med Rep; 2015 Sep; 12(3):4370-4375. PubMed ID: 26130140
[TBL] [Abstract] [Full Text] [Related]
9. [Atypical metastatic breast localization in lung cancer].
Serraille A; Barazzutti H; Greillier L; Barlesi F
Rev Mal Respir; 2015 Nov; 32(9):953-5. PubMed ID: 26037683
[TBL] [Abstract] [Full Text] [Related]
10. Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC.
Bosc C; Ferretti GR; Cadranel J; Audigier-Valette C; Besse B; Barlesi F; Decroisette C; Lantuejoul S; Arbib F; Moro-Sibilot D
Target Oncol; 2015 Jun; 10(2):247-53. PubMed ID: 25119973
[TBL] [Abstract] [Full Text] [Related]
11. Lung cancer during pregnancy: an unusual case.
Neves I; Mota PC; Hespanhol VP
Rev Port Pneumol; 2014; 20(1):46-9. PubMed ID: 23910397
[TBL] [Abstract] [Full Text] [Related]
12. Lung cancer and pregnancy.
Sarıman N; Levent E; Yener NA; Orki A; Saygı A
Lung Cancer; 2013 Mar; 79(3):321-3. PubMed ID: 23254266
[TBL] [Abstract] [Full Text] [Related]